Breaking News

Pfizer Launches Cost-Cutting Initiative as U.S. Govt. Amends Paxlovid Supply Pact

Drop in COVID-19 product sales spurs multi-year cost realignment program involving undisclosed layoffs in an effort to save $3.5 billion through 2024.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

The U.S. government has amended its supply agreement with Pfizer for Paxlovid and the company has updated its Full-Year 2023 Guidance. A cost-cutting initiative aims to save $3.5 billion through 2024 due to a drop in the sales of its COVID-19 products.   Under the terms of the revised supply agreement with the U.S. government for COVID-19 drug Paxlovid (nirmatrelvir/ritonavir), the government will return to Pfizer approximately 7.9 million doses of Paxlovid.   Paxlovid was initially given an...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters